2023 - Research.com Medicine in United Kingdom Leader Award
The scientist’s investigation covers issues in Breast cancer, Pathology, Internal medicine, Oncology and Cancer. His studies link Cancer research with Breast cancer. His studies in Pathology integrate themes in fields like Basal and Molecular pathology.
His research integrates issues of Endocrinology and Surgery in his study of Internal medicine. His Oncology research is multidisciplinary, incorporating perspectives in Multivariate analysis, Lymph node, Stage, Survival analysis and Adjuvant therapy. The Mammary gland study combines topics in areas such as Epidermal growth factor and Pathological.
Breast cancer, Internal medicine, Pathology, Oncology and Cancer research are his primary areas of study. His Breast cancer research integrates issues from Immunohistochemistry and Tissue microarray. His research ties Endocrinology and Internal medicine together.
Ian O. Ellis usually deals with Pathology and limits it to topics linked to Ductal carcinoma and Radiology. His Oncology study combines topics in areas such as Gynecology, Metastasis, Proportional hazards model, Biomarker and Survival analysis. His biological study spans a wide range of topics, including Cancer cell, Immunology and DNA repair.
His primary areas of study are Breast cancer, Internal medicine, Oncology, Immunohistochemistry and Cancer research. Breast cancer is the subject of his research, which falls under Cancer. In his research on the topic of Oncology, Androgen receptor is strongly related with Triple-negative breast cancer.
His work carried out in the field of Cancer research brings together such families of science as Cancer cell, Immunology, Messenger RNA, Disease and DNA repair. His Tissue microarray study integrates concerns from other disciplines, such as Subclass and Risk factor. His Pathology study combines topics from a wide range of disciplines, such as Ductal carcinoma, Transcriptome, Metastasis and Tumor-infiltrating lymphocytes.
Ian O. Ellis mainly investigates Breast cancer, Internal medicine, Oncology, Cancer research and Immunohistochemistry. His Breast cancer research is multidisciplinary, relying on both Carcinoma, Cohort and Pathology. He has researched Internal medicine in several fields, including Fusion gene, Biological evolution and MEDLINE.
His Oncology research incorporates themes from Human Epidermal Growth Factor Receptor 2, Tumour heterogeneity and Lymph node. Ian O. Ellis combines subjects such as Cell growth, Cyclin E and Messenger RNA, Gene, DNA repair with his study of Cancer research. Ian O. Ellis has included themes like Biomarker, Low protein, Triple-negative breast cancer and GPER in his Immunohistochemistry study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C.W. Elston;I.O. Ellis.
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Antonio C Wolff;M Elizabeth Hale Hammond;Kimberly H Allison;Brittany E Harvey.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis;Christina Curtis;Sohrab P Shah;Suet-Feung Chin;Gulisa Turashvili.
Pathological prognostic factors in breast cancer.
Christopher W. Elston;Ian O. Ellis;Sarah E. Pinder.
Critical Reviews in Oncology Hematology (1999)
WHO classification of tumours of the breast
Sunil R. Lakhani;Ian O. Ellis;Stuart J. Schnitt;Puay Hoon Tan.
Prognostic markers in triple-negative breast cancer
Emad A. Rakha;Maysa E. El-Sayed;Andrew R. Green;Andrew H. S. Lee.
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M.A. Mahmoud;Emma Claire Paish;Desmond G. Powe;R. Douglas Macmillan.
Journal of Clinical Oncology (2011)
The Nottingham Prognostic Index in primary breast cancer.
Marcus H. Galea;Roger W. Blamey;Christopher E. Elston;Ian O. Ellis.
Breast Cancer Research and Treatment (1992)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C. Wolff;M. Elizabeth Hale Hammond;Kimberly H. Allison;Brittany E. Harvey.
Archives of Pathology & Laboratory Medicine (2018)
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies
Fiona M. Blows;Kristy E. Driver;Marjanka K. Schmidt;Annegien Broeks.
PLOS Medicine (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: